iTeos Therapeutics to Participate in Upcoming September Investor Conferences
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced participation in five virtual investor conferences throughout September 2021. Key events include the KBC Securities Life Sciences Conference on September 7 and the Wells Fargo Virtual Healthcare Conference on September 9-10. Additionally, iTeos will present at the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, the H.C. Wainwright Annual Global Investment Conference on September 13, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Audio webcasts will be accessible on their website.
- None.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company management will participate in five upcoming virtual investor conferences in September:
- KBC Securities Life Sciences Conference
Format: Management one-on-ones
Date: September 7, 2021
- Wells Fargo Virtual Healthcare Conference
Format: Management one-on-ones
Date: September 9-10, 2021
- Morgan Stanley 19th Annual Global Healthcare Conference
Format: Management one-on-ones
Date: September 9-10 and 13-15, 2021
- H.C. Wainwright 23rd Annual Global Investment Conference
Format: On demand presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
Date/Time: Monday, September 13, 2021 at 7:00 a.m. ET
- Cantor Fitzgerald Global Healthcare Conference
Format: Live presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
Date/Time: Monday, September 27, 2021 at 2:40 p.m. ET
Audio webcasts of the presentations will be available on the Investor section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
FAQ
What is the schedule for iTeos Therapeutics investor conferences in September 2021?
Who is presenting at the H.C. Wainwright Global Investment Conference for ITOS?
When will audio webcasts be available for iTeos Therapeutics presentations?
What product candidates are in development at iTeos Therapeutics?
How is iTeos Therapeutics addressing cancer immunosuppression?
